Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 42

Quick test can curb antimicrobial resistance, identifying bacteria and antibiotic susceptibility in under 40 minutes

McGill researchers have developed a diagnostic system capable of identifying bacteria—and determining which antibiotics can stop them—in just 36 minutes, a major advance in the global effort to curb antimicrobial resistance (AMR). Current clinical testing methods typically take 48 to 72 hours, leaving physicians without timely guidance.

The researchers say this innovation arrives at a critical moment due to the urgency of the AMR crisis, which arises from bacteria developing resistance to antibiotics.

“We are losing the race against antimicrobial resistance,” said Sara Mahshid, associate professor in the Department of Bioengineering and lead author on the Nature Nanotechnology study. “Every year, more than one million people die, more than from HIV/AIDS or malaria, and delayed treatment is a major driver. Rapid testing isn’t a luxury; it’s the missing link between diagnosis and survival.”

From cryogenic to red-hot: Optical temperature sensing from 77 K to 873 K

An international collaboration involving researchers from the University of Innsbruck has developed a novel luminescent material that enables particularly robust and precise optical temperature sensing across an exceptionally broad temperature range.

Optical luminescence thermometry has been gaining increasing attention, as it allows contactless temperature measurement even under extreme conditions. A key concept in this field is so-called ratiometric Boltzmann thermometry, in which the intensity ratio of two thermally coupled emission transitions directly follows the temperature. The performance of such thermometers crucially depends on the electronic structure of the luminescent ion and its incorporation into the host structure.

In a recent study, the two first authors, Gülsüm Kinik from the research group of Prof. Markus Suta at Heinrich Heine University Düsseldorf and Ingo Widmann from the research group of Prof. Hubert Huppertz at the Department of General, Inorganic and Theoretical Chemistry at the University of Innsbruck, reported the compound Al0.993 Cr0.007 B4 O6 N, which stands out as an exceptionally high-performance luminescence thermometer. The material is based on Cr3+ ions embedded in an almost ideal octahedral coordination environment, resulting in a particularly well-defined energy level scheme.

‘Zombie’ Remnants of COVID-19 Hunt In Packs And Kill Our Immune Cells

‘Zombie’ coronavirus fragments not only help drive inflammation in long-COVID, but also destroy our immune cells.

A recent study by an international team of more than 30 authors reveals how the destruction of the virus within our body leaves dangerous protein fragments that target specific immune cells, which may explain some of the debilitating consequences millions of people with long-COVID now face.

“These fragments target a specific kind of curvature on the membranes of cells,” explains bioengineer Gerard Wong from the University of California, Los Angeles. “Cells that are spiky, that are star-shaped, or that have lots of tentacles end up getting preferentially suppressed.”

A mesoscale optogenetics system for precise and robust stimulation of the primate cortex

Li et al. present a microLED-based mesoscale optogenetic system for centimeter-scale, million-pixel primate cortical stimulation. Optogenetically evoked saccades with accurate retinotopic organization remain stable for over a year, demonstrating precise, robust, and durable neuromodulation and charting a path toward next-generation optical brain-computer interfaces and visual prostheses.

Breathing in the past: How museums can use biomolecular archaeology to bring ancient scents to life

Recent advances in biomolecular archaeology have revealed that ancient objects can retain the molecular fingerprints of past aromatic practices. These molecules provide unprecedented insight into ancient perfumery, medicine, ritual, and daily life.

In a publication in Frontiers in Environmental Archaeology, an interdisciplinary research team led by archaeo-chemist Barbara Huber (Max Planck Institute of Geoanthropology and the University of Tübingen), shows how museums can use this molecular evidence to engage audiences with the sensory worlds of the past. The team combined their expertise to create a new workflow for converting biomolecular data into accessible, visitor-ready olfactory recreations.

“This research represents a significant shift in how scientific results can be shared beyond academic publications,” explains Huber.

Real-time imaging captures contact between cells and between a single neuron’s extensions

Living organisms are made up of hundreds of thousands of cells that cooperate to create the organs and systems that breathe, eat, move, and think. Now, researchers from Japan have developed a new way to track how and when cells touch each other to work together in these ways. In a study published in January in Cell Reports Methods, researchers from The University of Osaka reported the development of fluorescent markers for monitoring cell communication under a microscope.

Cells communicate with each other by making cell-to-cell contacts, and fluorescent markers are often used to visualize these contacts. The most commonly used marker for this purpose is green fluorescent protein (GFP). GFP can be divided into two halves that are expressed on different cells. When the cells touch, the two halves come together to form a complete GFP, letting off a fluorescent signal.

“Split GFP is useful for detecting the formation of stable connections between cells,” says lead author of the study Takashi Kanadome. “But because it takes time for the rejoined GFP to emit its signal and the association is irreversible, this approach cannot be used to detect dynamic cell–cell interactions in real-time.”

Community Series in Vaccines and approaches that target trained immunity in COVID-19: Immunological mechanisms of action and delivery: Volume II

2024 This is a first of its kind univversal covid 19 vaccine that would allow for a one time shot that is good for current versions of the virus and future versions aswell.

A universal recombinant adenovirus type-5 (Ad5) vaccine against COVID19 (Ad-US) was constructed, and immunogenicity and broad-spectrum of Ad5-US were evaluated with both intranasal and intramuscular immunization routes. The humoral immune response of Ad5-US in serum and bronchoalveolar lavage fluid were evaluated by the enzyme-linked immunosorbent assay (ELISA), recombinant vesicular stomatitis virus based pseudovirus neutralization assay, and angiotensin-converting enzyme-2 (ACE2)-binding inhibition assay. The cellular immune response and Th1/Th2 biased immune response of Ad5-US were evaluated by the IFN-γ ELISpot assay, intracellular cytokine staining, and Meso Scale Discovery (MSD) profiling of Th1/Th2 cytokines. Intramuscular priming followed by an intranasal booster with Ad5-US elicited the broad-spectrum and high levels of IgG, IgA, pseudovirus neutralizing antibody (PNAb), and Th1-skewing of the T-cell response. Overall, the adenovirus type-5 vectored universal SARS-CoV-2 vaccine Ad5-US was successfully constructed, and Ad5-US was highly immunogenic and broad spectrum. Intramuscular priming followed by an intranasal booster with Ad5-US induced the high and broad spectrum systemic immune responses and local mucosal immune responses.

According to the World Health Organization, as of March 15, 2024, over 774 million COVID-19 cases and almost 7 million related deaths had been reported globally. A total of 13.59 billion doses of COVID-19 vaccines have been reportedly administered globally, leading to a vaccination rate of 69.7%. At present, at least 24 types of COVID-19 vaccines have been authorized for emergency use in various countries. According to the list of global COVID-19 candidate vaccines published on the WHO website, a total of 183 candidate vaccines are in clinical development and 199 candidate vaccines are in the preclinical evaluation stage as of April 8, 2023. Recombinant protein subunit vaccines account for the greatest proportion of vaccines in clinical development (59 vaccines, 32%), followed by RNA vaccines (43 vaccines, 24%).

/* */